Bermekimab
IL1A | |
|---|---|
| Clinical data | |
| Trade names | Xilonix |
| Other names | MABp1 |
| Routes of administration | intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6464H10024N1736O2000S44 |
| Molar mass | 145468.09 g·mol−1 |
BermekimabIL1A).[2] As of March 2017[update], bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.[4]
Bermekimab is being developed by XBiotech Inc.[5]
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
- PMID 24746841.
- ^ Clinical trial number NCT01767857 for "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)" at ClinicalTrials.gov
- ^ Clinical trial number NCT03496974 for "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis" at ClinicalTrials.gov
- ^ "Xilonix True Human monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.